Please note that the following is an unofficial English translation of the original Japanese text of the press release of Nichi-Iko Pharmaceutical Co., Ltd. Nichi-Iko Pharmaceutical Co., Ltd. provides this translation for reference and convenience purposes only and without any warranty as to its accuracy or otherwise. In the event of any discrepancy between this translation and the Japanese original, the latter shall prevail.



September 30, 2013

To whom it may concern:

Company name: Nichi-Iko Pharmaceutical Co., Ltd.

(Securities code: 4541 Tokyo Stock Exchange, First Section)

Representative: Yuichi Tamura

President and CEO

Contact: Noboru Inasaka

Managing Executive Officer and General

Manager of Management Division

(Tel: 076-432-2121)

Notice Concerning Determination of Terms of Issuance of Stock Options (Stock Acquisition Rights)

Nichi-Iko Pharmaceutical Co., Ltd. (the "Company") hereby announces that undetermined items regarding the terms and conditions of the stock acquisition rights issued as stock options to Executive Officers and employees of the Company and Directors and employees of the Company's subsidiaries, as resolved at the meeting of Board of Directors held on September 9, 2013, have been determined as follows.

Particulars

1. Total Number of the Stock Acquisition Rights

420 (100 shares per one stock acquisition right)

2. Class and Number of Shares Underlying the Stock Acquisition Rights

Common stock of the Company: 42,000 shares

3. Value of the Property to be Contributed upon Exercise of the Stock Acquisition Rights

2,290 yen per share

Please note that the following is an unofficial English translation of the original Japanese text of the press release of Nichi-Iko Pharmaceutical Co., Ltd. Nichi-Iko Pharmaceutical Co., Ltd. provides this translation for reference and convenience purposes only and without any warranty as to its accuracy or otherwise. In the event of any discrepancy between this translation and the Japanese original, the latter shall prevail.

4. Category and Number of Persons Eligible to Receive Allocation

Category	Number of people	Allotted amount
Executive Officers of the Company	7	16
Employees of the Company	280	369
Directors of the Company's subsidiaries	2	5
Employees of the Company's subsidiaries	19	30

(For Your Reference)

Date of the resolution of the meeting of Board of Directors at which the matters to be discussed at

the Annual General Meeting of Shareholders were determined: May 14, 2013

Date of the resolution of the Annual General Meeting of Shareholders: June 21, 2013

Date of the resolution of the Board of Directors for issuance: September 9, 2013

Allotment date: September 30, 2013

END